Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
Status:
Completed
Trial end date:
2021-04-27
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, Phase 4 study evaluating the effect of GO on the QTc,
pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adult and
pediatric patients with relapsed or refractory CD33-positive AML.